Resilience is a North American contract development and manufacturing organization (CDMO) focused on delivering high-quality, scalable manufacturing solutions for advanced therapies. With all manufacturing in North America, Resilience provides integrated capabilities spanning biologics drug substance, and sterile drug product manufacturing, device assembly and packaging for both small and large molecules. The company partners with leading pharmaceutical and biotech companies to bring complex medicines to market faster and more reliably. Resilience is building a streamlined, high-performance domestic network designed to meet the evolving needs of clinical and commercial-stage innovators.
Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and economics. Celularity’s innovative approach to cell therapy harnesses the unique therapeutic potential locked within the postpartum placenta. Through nature’s immunotherapy engine – the placenta – Celularity is leading the next evolution of cellular medicine with placenta-derived T cells, NK cells, and pluripotent stem cells to target unmet and underserved clinical needs in cancer, infectious and degenerative diseases. To learn more visit celularity.com.
Alkahest, a subsidiary of Grifols, is developing therapies derived from blood to treat neurological diseases, with an emphasis on age-related cognitive decline -- key medical challenges of our generation. The company’s breakthrough research has demonstrated that factors in blood plasma of young mice are able to reverse brain deficits in normal aging and Alzheimer’s disease models in mice. Clinical studies are being conducted in patients with different types of dementia and other neurodegenerative diseases. Alkahest is based in San Carlos, Calif., while Grifols, a global healthcare company, is headquartered in Barcelona, Spain.